Mobile website
Archive > Volume 22 Issue 4 > 2015,22(4):505-508. DOI:10.3872/j.issn.1007-385X.2015.04.017 Prev Next
Clinical Research
Effects of autologous CIK cells immunotherapy on the immune function and quality of life of cancer patients
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective : The aim of the present study is to evaluate the effects of autologous cytokine-induced killer cells (CIK) immunotherapy on immune function and quality of life of cancer patients. Methods: We performed a retrospective analysis of 58 cancer patients who received CIK immunotherapy in our hospital. The T lymphocyte in their peripheral blood samples drew before and after the treatment were analyzed by flow cytometry for CD3+, CD3+CD4+, CD3+CD8+,CD3-CD16+CD56+ and CD3+CD16+CD56+ subpopulations. Patients were assessed with the WHO QOL-BREF questionnaires to evaluate their quality of life. Treatment-related adverse reactions during treatment were also surveyed. Results: In the culture for generating CIK, the levels of CD3+ T lymphocytes, CD3+CD4+ T helper cells, CD3+CD8+ cytotoxic T cells were (82.79±11.98)%, (30.32±11.23)%, and (49.10±11.65)% respectively. The ratio of CD4+ and CD8+ T cells was 0.67±0.34. Notably, the levels of CD3+CD16+CD56+ CIK cells and CD3-CD16+CD56+ NK cells were (16.58±11.83)% and (13.74±8.66)%. Comparing the two peripheral blood samples from each patient, the percentages of CD3+ T lymphocytes, CD3+CD4+ T helper cells, CD3+CD8+ cytotoxic T cells, and CD3+CD16+CD56+CIK subsets were all significantly increased after the treatment (P<0.05), whereas the percentage of CD3-CD16+CD56+NK cell percentage decreased significantly (P<0.05). The QOL-BREF of patients were also improved significantly (P<005), and the treatment-related adverse reactions were well-tolerated in most patients. Conclusion: CIK therapy is safe and effective in improving quality of life and immune functions of patients with malignant tumors.
Keywords:
Project Supported:
Population System of Shenzhen City (No. 201402025)
Clc Number:
